Opioid Peptides Control Sex Hormone Production in Ovarian Cells

Mu-opioid receptor agonists inhibited both basal and LH-stimulated progesterone and androstenedione production in porcine ovarian theca cells, revealing opioid peptide control of ovarian steroidogenesis.

Kaminski, T et al.·Animal reproduction science·2003·Preliminary Evidencein-vitro
RPEP-00832In VitroPreliminary Evidence2003RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Mu-opioid receptor agonists inhibited basal and LH-stimulated progesterone and androstenedione production in porcine theca cells in a dose-dependent manner, demonstrating direct opioid peptide control of ovarian steroidogenesis.

Key Numbers

How They Did This

In-vitro study using cultured porcine theca cells from large follicles. Mu-opioid receptor agonists at various concentrations (1-1000 nM) with and without LH stimulation. Progesterone and androstenedione measured.

Why This Research Matters

Opioid control of ovarian hormones explains why chronic opioid use causes menstrual irregularities and fertility problems, and why stress and pain affect reproductive function.

The Bigger Picture

The opioid-reproductive connection is clinically significant. Chronic opioid therapy, endogenous opioid changes during stress, and the opioid system's role in polycystic ovary syndrome all involve this ovarian opioid regulation.

What This Study Doesn't Tell Us

In-vitro porcine theca cells. Human ovarian cells may respond differently. Only mu-receptor tested; delta and kappa effects unknown.

Questions This Raises

  • ?Does chronic opioid medication use impair fertility through this mechanism?
  • ?Is ovarian opioid signaling altered in PCOS?
  • ?Could opioid antagonists (naltrexone) improve fertility in some women?

Trust & Context

Key Stat:
Hormones suppressed Mu-opioid activation directly reduced progesterone and androstenedione in ovarian cells — opioids don't just affect pain, they affect fertility
Evidence Grade:
Preliminary in-vitro evidence with clear dose-response in a relevant reproductive tissue model.
Study Age:
Published in 2003. Opioid-induced hypogonadism is now a recognized clinical entity requiring management in chronic opioid patients.
Original Title:
The regulation of steroidogenesis by opioid peptides in porcine theca cells.
Published In:
Animal reproduction science, 78(1-2), 71-84 (2003)
Database ID:
RPEP-00832

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Do opioids affect fertility?

Yes — this study shows opioid peptides directly suppress sex hormone production in ovarian cells. This explains why chronic opioid use (pain medications, heroin) causes menstrual irregularities and fertility problems.

Could this be reversed?

Potentially. If opioids suppress ovarian hormones through mu-receptors, naltrexone (an opioid blocker) might restore normal hormone production. This approach is being studied for opioid-induced hypogonadism.

Read More on RethinkPeptides

Cite This Study

RPEP-00832·https://rethinkpeptides.com/research/RPEP-00832

APA

Kaminski, T; Siawrys, G; Bogacka, I; Okrasa, S; Przala, J. (2003). The regulation of steroidogenesis by opioid peptides in porcine theca cells.. Animal reproduction science, 78(1-2), 71-84.

MLA

Kaminski, T, et al. "The regulation of steroidogenesis by opioid peptides in porcine theca cells.." Animal reproduction science, 2003.

RethinkPeptides

RethinkPeptides Research Database. "The regulation of steroidogenesis by opioid peptides in porc..." RPEP-00832. Retrieved from https://rethinkpeptides.com/research/kaminski-2003-the-regulation-of-steroidogenesis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.